Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial

By sjmartinez • June 4, 2024

Yarur AJ, Chiorean MV, Panés J, Jairath V, Zhang J, Rabbat CJ, Sandborn WJ, Vermeire S, Peyrin-Biroulet L. Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial. J Crohns Colitis. 2024 Jun 3;18(6):885-894. doi: 10.1093/ecco-jcc/jjae007. PMID: 38245818; PMCID: PMC11147797.

Tags: Cedars Sinai DoM, Digestive Diseases, endoscopic improvement–histologic remission, Etrasimod, mucosal healing, Publications, S1P receptor modulator, ulcerative colitis

Related Posts

Detecting structural heart disease from electrocardiograms using AI

Poterucha TJ, Jing L, Ricart RP, Adjei-Mosi M, Finer J, Hartzel D, Kelsey C, Long A, Rocha D, Ruhl JA, vanMaanen D, Probst MA, Daniels[...]

Phase 2a Study of Baxdrostat in Primary Aldosteronism

Turcu AF, Freeman MW, Bancos I, Ben-Shlomo A, Hamidi O, Hamrahian AH, Huang W, Kirschner LS, Sam R, Mallappa A, Tuyishimire B, Lihn AS, Perl[...]

Modulation of the PTPRS proteoglycan switch by antibodies binding to the membrane-proximal fibronectin-type III domain

Hein Da Rosa T, Ramsey SH, Lee JJ, Kozlova NY, Zhao Z, Kim J, Schneider AC, Li S, Katiki M, Firestein GS, Murali R, Santelli[...]